Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 871 to 885 of 7707 results

  1. Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (TA946)

    Evidence-based recommendations on olaparib (Lynparza) with bevacizumab (Avastin) for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.

  2. Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA976)

    NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because Daiichi Sankyo did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA976

  3. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)

    Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.

  4. Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) (TA978)

    NICE is unable to make a recommendation on zanubrutinib (Brukinsa) with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is because BeiGene has requested a delay to the evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA978

  5. Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)

    Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.

  6. Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

    Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

  7. Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)

    NICE is unable to make a recommendation about the use in the NHS of baricitinib (Olumiant) for treating juvenile idiopathic arthritis in people 2 years and over. This is because Eli Lilly did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA982

  8. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  9. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)

    Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.

  10. Arranging services for people with a learning disability and behaviour that challenges

    A quick guide for commissioners People with a learning disability (or autism and a learning disability) and behaviour that challenges should have the

  11. Better home care for older people

    A quick and easy-to-read guide to the standard of care you should expect from a home care provider.

  12. Creating a safeguarding culture

    A quick guide to creating a safeguarding culture

  13. Developing a positive working culture for supporting disabled children and young people with severe complex needs

    NICE'S quick guide to developing a positive working culture for supporting disabled children and young people with severe complex needs

  14. Effective record keeping and ordering of medicines

    A quick guide for home care managers providing medicines support

  15. Evidence for strengths and asset-based outcomes

    A quick guide for social workers Strengths and asset-based approaches in social care focus on what individuals and communities have and how they can...